688319 欧林生物
已收盘 05-20 15:00:01
资讯
新帖
简况
【机构调研记录】红土创新基金调研欧林生物
证券之星 · 05-15
【机构调研记录】红土创新基金调研欧林生物
股市必读：欧林生物（688319）5月14日披露最新机构调研信息
证券之星 · 05-15
股市必读：欧林生物（688319）5月14日披露最新机构调研信息
山西证券：首次覆盖欧林生物给予增持评级
证券之星 · 05-14
山西证券：首次覆盖欧林生物给予增持评级
5月13日欧林生物创60日新高，兴全社会价值三年持有混合基金重仓该股
证券之星 · 05-13
5月13日欧林生物创60日新高，兴全社会价值三年持有混合基金重仓该股
欧林生物：UBS、中信资管等多家机构于5月8日调研我司
证券之星 · 05-11
欧林生物：UBS、中信资管等多家机构于5月8日调研我司
每周股票复盘：欧林生物（688319）一季度净利增484.36%
证券之星 · 05-02
每周股票复盘：欧林生物（688319）一季度净利增484.36%
图解欧林生物一季报：第一季度单季净利润同比增长484.36%
证券之星 · 04-29
图解欧林生物一季报：第一季度单季净利润同比增长484.36%
4月29日欧林生物涨7.04%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 04-29
4月29日欧林生物涨7.04%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）股东户数下降3.55%
证券之星 · 04-05
每周股票复盘：欧林生物（688319）股东户数下降3.55%
【机构调研记录】诺安基金调研广电计量、欧林生物
证券之星 · 04-02
【机构调研记录】诺安基金调研广电计量、欧林生物
【机构调研记录】华西基金调研欧林生物
证券之星 · 04-02
【机构调研记录】华西基金调研欧林生物
图解欧林生物年报：第四季度单季净利润同比下降250.73%
证券之星 · 03-31
图解欧林生物年报：第四季度单季净利润同比下降250.73%
3月23日欧林生物跌7.24%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-23
3月23日欧林生物跌7.24%，兴全社会价值三年持有混合基金重仓该股
每周股票复盘：欧林生物（688319）因股价涨幅达15%登龙虎榜
证券之星 · 03-22
每周股票复盘：欧林生物（688319）因股价涨幅达15%登龙虎榜
3月18日欧林生物（688319）龙虎榜数据：机构净买入3560.28万元，北向资金净买入860.17万元
证券之星 · 03-18
3月18日欧林生物（688319）龙虎榜数据：机构净买入3560.28万元，北向资金净买入860.17万元
3月16日欧林生物跌8.24%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-16
3月16日欧林生物跌8.24%，兴全社会价值三年持有混合基金重仓该股
3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-09
3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股
3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股
证券之星 · 03-04
3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股
新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等
智通财经 · 03-02
新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等
股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元
证券之星 · 03-02
股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元
加载更多
公司概况
公司名称：
成都欧林生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-06-08
主营业务：
成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗。
发行价格：
9.88
{"stockData":{"symbol":"688319","market":"SH","secType":"STK","nameCN":"欧林生物","latestPrice":39.17,"timestamp":1779260401000,"preClose":40.7,"halted":0,"volume":9397464,"delay":0,"changeRate":-0.0376,"floatShares":405000000,"shares":405999999,"eps":0.1394,"marketStatus":"已收盘","change":-1.53,"latestTime":"05-20 15:00:01","open":40.49,"high":40.78,"low":38.91,"amount":372000000,"amplitude":0.0459,"askPrice":39.17,"askSize":60,"bidPrice":39.16,"bidSize":58,"shortable":0,"etf":0,"ttmEps":0.1394,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779327000000},"marketStatusCode":5,"adr":0,"adjPreClose":40.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779240600000,1779247800000],[1779253200000,1779260400000]],"highLimit":44.77,"lowLimit":36.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":405708900,"isCdr":false,"pbRate":17.07,"roa":"--","peRate":280.989957,"roe":"2.96%","epsLYR":0.0549,"committee":-0.657521,"marketValue":15892000000,"turnoverRate":0.0232,"status":1,"afterMarket":{"amount":7834,"volume":200,"close":39.17,"buyVolume":300,"sellVolume":0,"time":1779262437558,"indexStatus":"已收盘 05-20 15:30:00","preClose":40.7},"floatMarketCap":15880000000},"requestUrl":"/m/hq/s/688319","defaultTab":"news","newsList":[{"id":"2635272799","title":"【机构调研记录】红土创新基金调研欧林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635272799?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:01","pubTimestamp":1778803317,"startTime":"0","endTime":"0","summary":"红土创新基金成立于2014年，截至目前，资产管理规模194.83亿元，排名125/212；资产管理规模92.75亿元，排名123/212；管理公募基金数46只，排名110/212；旗下公募基金经理13人，排名95/212。旗下最近一年表现最佳的公募基金产品为红土创新新兴产业混合A，最新单位净值为4.95，近一年增长319.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500008471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742123","title":"股市必读：欧林生物（688319）5月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742123","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635742123?lang=zh_cn&edition=full","pubTime":"2026-05-15 01:42","pubTimestamp":1778780533,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，欧林生物报收于38.64元，下跌2.18%，换手率2.69%，成交量10.9万手，成交额4.29亿元。来自机构调研要点：公司预计重组金葡菌疫苗III期临床试验将在2026年上半年内揭盲，具体时间受多种因素影响。未来公司将加强市场开拓、产品推广及成本费用管控，保障经营性现金流健康。答：公司持续推进重组金葡菌疫苗III期临床收尾工作，根据目前进展，预计2026年上半年内进行揭盲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635713770","title":"山西证券：首次覆盖欧林生物给予增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2635713770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635713770?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:10","pubTimestamp":1778753454,"startTime":"0","endTime":"0","summary":"山西证券股份有限公司邓周宇,魏赟,陈进近期对欧林生物进行研究并发布了研究报告《专注“超级细菌”疫苗赛道，金葡菌疫苗或即将实现突破》，首次覆盖欧林生物给予增持评级。欧林生物主营破伤风疫苗，是公司最核心上市销售产品；在研创新疫苗主攻院内耐药菌感染赛道，核心在研产品金葡菌疫苗已进入3期临床尾声，有望成为全球首个上市产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400034529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","002500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635820170","title":"5月13日欧林生物创60日新高，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635820170","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635820170?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:31","pubTimestamp":1778661116,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日欧林生物创60日新高，收盘报39.5元，当日涨3.84%，换手率3.49%，成交量14.16万手，成交额5.43亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。兴全社会价值三年持有混合目前规模为13.57亿元，最新净值2.4902，较上一交易日上涨0.37%，近一年上涨60.66%。该公募基金现任基金经理为谢治宇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300029514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634283581","title":"欧林生物：UBS、中信资管等多家机构于5月8日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2634283581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634283581?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:04","pubTimestamp":1778497441,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月11日欧林生物发布公告称UBS、中信资管、广发证券、摩根士丹利基金、Sage Partner于2026年5月8日调研我司。欧林生物2026年一季报显示，一季度公司主营收入1.58亿元，同比上升80.37%；归母净利润2718.93万元，同比上升484.36%；扣非净利润2327.8万元，同比上升311.18%；负债率53.9%，投资收益12.51万元，财务费用421.38万元，毛利率91.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100029085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632364141","title":"每周股票复盘：欧林生物（688319）一季度净利增484.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632364141","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632364141?lang=zh_cn&edition=full","pubTime":"2026-05-02 02:29","pubTimestamp":1777660149,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，欧林生物报收于30.88元，较上周的28.47元上涨8.47%。本周，欧林生物4月30日盘中最高价报32.18元。本周关注点来自业绩披露要点：欧林生物2026年一季报显示，归母净利润2718.93万元，同比上升484.36%。股本股东变化股东户数变动截至2026年3月31日，欧林生物股东户数为9522.0户，较2月28日增加529.0户，增幅5.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631059230","title":"图解欧林生物一季报：第一季度单季净利润同比增长484.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631059230","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631059230?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:31","pubTimestamp":1777458663,"startTime":"0","endTime":"0","summary":"证券之星消息，欧林生物2026年一季报显示，一季度公司主营收入1.58亿元，同比上升80.37%；归母净利润2718.93万元，同比上升484.36%；扣非净利润2327.8万元，同比上升311.18%；负债率53.9%，投资收益12.51万元，财务费用421.38万元，毛利率91.84%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900058919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631156038","title":"4月29日欧林生物涨7.04%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631156038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631156038?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:31","pubTimestamp":1777451501,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日欧林生物涨7.04%，收盘报29.94元，换手率2.76%，成交量11.19万手，成交额3.27亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为37.48。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900052117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616415","title":"每周股票复盘：欧林生物（688319）股东户数下降3.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616415","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616415?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:19","pubTimestamp":1775326748,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，欧林生物报收于29.58元，较上周的29.74元下跌0.54%。本周，欧林生物3月31日盘中最高价报31.2元。股本股东变化截至2026年2月28日，欧林生物股东户数为8993.0户，较2025年12月31日减少331.0户，减幅为3.55%。户均持股数量由上期的4.35万股上升至4.51万股，户均持股市值为124.06万元。业绩披露要点欧林生物2025年年报显示，公司主营收入为7.04亿元，同比增长19.58%；归母净利润为2226.01万元，同比增长7.24%；扣非净利润为990.79万元，同比下降11.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624528490","title":"【机构调研记录】诺安基金调研广电计量、欧林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2624528490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624528490?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:12","pubTimestamp":1775088771,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月1日披露的机构调研信息，诺安基金近期对2家上市公司进行了调研，相关名单如下：1）广电计量 调研纪要：2025年，公司加快向商业航天、低空经济、人工智能等高成长赛道转型，高毛利业务带动净利率提升。2）欧林生物 调研纪要：公司重组金葡菌疫苗Ⅲ期临床试验已于2025年5月完成全部受试者入组，预计2025年上半年揭盲。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200005279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002967","BK0239","688319","BK0221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624489528","title":"【机构调研记录】华西基金调研欧林生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2624489528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624489528?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:12","pubTimestamp":1775088730,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月1日披露的机构调研信息，华西基金近期对1家上市公司进行了调研，相关名单如下：1）欧林生物 调研纪要：公司重组金葡菌疫苗Ⅲ期临床试验已于2025年5月完成全部受试者入组，预计2025年上半年揭盲。旗下最近一年表现最佳的公募基金产品为华西优选成长一年持有混合A，最新单位净值为1.34，近一年增长26.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200005224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623325302","title":"图解欧林生物年报：第四季度单季净利润同比下降250.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623325302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623325302?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:52","pubTimestamp":1774896759,"startTime":"0","endTime":"0","summary":"证券之星消息，欧林生物2025年年报显示，当年度公司主营收入7.04亿元，同比上升19.58%；归母净利润2226.01万元，同比上升7.24%；扣非净利润990.79万元，同比下降11.38%；其中2025年第四季度，公司单季度主营收入1.97亿元，同比下降2.46%；单季度归母净利润-2521.96万元，同比下降250.73%；单季度扣非净利润-3013.47万元，同比下降361.75%；负债率55.32%，投资收益49.78万元，财务费用1448.29万元，毛利率92.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100006474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621977635","title":"3月23日欧林生物跌7.24%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621977635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621977635?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:38","pubTimestamp":1774255081,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日欧林生物跌7.24%，收盘报27.3元，换手率2.48%，成交量10.07万手，成交额2.83亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621379199","title":"每周股票复盘：欧林生物（688319）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2621379199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621379199?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:43","pubTimestamp":1774122190,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，欧林生物报收于29.43元，较上周的31.31元下跌6.0%。本周，欧林生物3月19日盘中最高价报32.29元。3月17日盘中最低价报26.3元。欧林生物当前最新总市值119.4亿元，在生物制品板块市值排名25/51，在两市A股市值排名1659/5190。本周关注点来自交易信息汇总：欧林生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620398292","title":"3月18日欧林生物（688319）龙虎榜数据：机构净买入3560.28万元，北向资金净买入860.17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620398292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620398292?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:14","pubTimestamp":1773825294,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年3月18日公布的交易公开信息显示，欧林生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年3月18日收盘，欧林生物报收于31.18元，上涨15.06%，换手率4.28%，成交量17.33万手，成交额5.1亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入3560.28万元，北向资金合计净买入860.17万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800029528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619727458","title":"3月16日欧林生物跌8.24%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619727458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619727458?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:23","pubTimestamp":1773649425,"startTime":"0","endTime":"0","summary":"证券之星消息，3月16日欧林生物跌8.24%，收盘报28.73元，换手率3.6%，成交量14.6万手，成交额4.39亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600021451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618646350","title":"3月9日欧林生物涨6.87%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646350?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:20","pubTimestamp":1773044435,"startTime":"0","endTime":"0","summary":"证券之星消息，3月9日欧林生物涨6.87%，收盘报30.5元，换手率3.06%，成交量12.4万手，成交额3.67亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900020746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616396580","title":"3月4日欧林生物涨5.68%，兴全社会价值三年持有混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616396580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616396580?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:21","pubTimestamp":1772612518,"startTime":"0","endTime":"0","summary":"证券之星消息，3月4日欧林生物涨5.68%，收盘报28.65元，换手率2.26%，成交量9.17万手，成交额2.59亿元。重仓欧林生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为兴证全球基金的兴全社会价值三年持有混合。该公募基金现任基金经理为谢治宇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400027747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334810","title":"新股消息 | 欧林生物(688319.SH)拟港股IPO 证监会要求说明业务是否涉及负面清单中基因诊疗技术开发应用等","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334810?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:22","pubTimestamp":1772454137,"startTime":"0","endTime":"0","summary":"证监会要求欧林生物补充说明其及下属公司实际业务是否涉及《外商投资准入特别管理措施》中人体干细胞、基因诊断与治疗技术开发和应用，并提供明确依据。据港交所2025年11月25日披露，欧林生物递表港交所主板，中信证券为独家保荐人。招股书显示，欧林生物是一家面向全球、创新驱动的生物制药公司，致力于创新疫苗的研究、开发、生产及商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK4588","BK0239","VT","688319"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616765758","title":"股市必读：欧林生物发布2025年度业绩快报，盈利0.222亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616765758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616765758?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:49","pubTimestamp":1772390948,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩快报欧林生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利0.222亿元，同比增长7.1%。公司公告汇总成都欧林生物科技股份有限公司2025年年度业绩快报成都欧林生物科技股份有限公司发布2025年年度业绩快报，营业总收入为704,160,325.32元，同比增长19.58%；营业利润为30,857,171.48元，同比增长44.80%；利润总额为31,893,209.89元，同比增长43.00%；归属于母公司所有者的净利润为22,231,741.55元，同比增长7.10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688319","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779263874032,"stockEarnings":[{"period":"1week","weight":0.0699},{"period":"1month","weight":0.3977},{"period":"3month","weight":0.5002},{"period":"6month","weight":0.7851},{"period":"1year","weight":1.7133},{"period":"ytd","weight":0.6049}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.2381},{"period":"ytd","weight":0.0506}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都欧林生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9522人(较上一季度增加5.88%)","perCapita":"42576股","listingDate":"2021-06-08","address":"四川省成都市郫都区高新区天欣路99号","registeredCapital":"40570万元","survey":" 成都欧林生物科技股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是吸附破伤风疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗。","listedPrice":9.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧林生物,688319,欧林生物股票,欧林生物股票老虎,欧林生物股票老虎国际,欧林生物行情,欧林生物股票行情,欧林生物股价,欧林生物股市,欧林生物股票价格,欧林生物股票交易,欧林生物股票购买,欧林生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧林生物(688319)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧林生物(688319)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}